Keisha Ballentine-Cargill
AIDS Clinical Trials Group(US)Group for the Analysis of Development(PE)
Publications by Year
Research Areas
Diabetes Treatment and Management, Diabetes Management and Research, Metabolism, Diabetes, and Cancer, Diabetes, Cardiovascular Risks, and Lipoproteins, Hepatitis C virus research
Most-Cited Works
- → Baseline Characteristics of Randomized Participants in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE)(2019)45 cited
- → Comparative Effects of Glucose-Lowering Medications on Kidney Outcomes in Type 2 Diabetes(2023)32 cited
- → HepB-CpG vs HepB-Alum Vaccine in People With HIV and Prior Vaccine Nonresponse(2024)31 cited
- → Optimization of Metformin in the GRADE Cohort: Effect on Glycemia and Body Weight(2020)25 cited
- → Association of Baseline Characteristics With Insulin Sensitivity and β-Cell Function in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness (GRADE) Study Cohort(2020)20 cited
- → Rationale and Design for a GRADE Substudy of Continuous Glucose Monitoring(2019)11 cited
- → Association of Glycemia, Lipids, and Blood Pressure With Cognitive Performance in People With Type 2 Diabetes in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE)(2021)7 cited
- → Glucose-Lowering Medications, Glycemia, and Cognitive Outcomes(2025)6 cited
- → Weight Gain Was Associated With Worsening Glycemia and Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes Independent of Diabetes Medication in the GRADE Randomized Controlled Trial(2025)3 cited
- → HepB-CpG Vaccine in People With HIV and Prior Nonresponse to HBV Vaccine(2025)2 cited